Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2079127 | 0.82 | KDM4E (0.31) | KDM4EGAAMAPT | |
| SCHEMBL1419590 | 0.80 | KDM4E (0.30) | KDM4EGAAMAPT | |
| SCHEMBL5684946 | 0.78 | GAA (0.32) | GAA | |
| SCHEMBL744771 | 0.78 | — | — | |
| SCHEMBL2035545 | 0.78 | ALDH1A1 (0.30) | ALDH1A1TSHRHSD17B10 | |
| SCHEMBL3045582 | 0.78 | EP300 (0.36) | GAAMAPTALDH1A1TSHR | |
| SCHEMBL8842929 | 0.78 | — | — | |
| SCHEMBL2319874 | 0.78 | GAA (0.32) | GAA | |
| SCHEMBL6008290 | 0.78 | EP300 (0.36) | GAAMAPTALDH1A1ALOX15TSHR | |
| SCHEMBL1704039 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8975259-B2 | Compositions and methods for inhibiting G protein signaling | UNIVERSITY OF ROCHESTER (US) | 2015-03-10 | — | — | US | claimed |
| US-20100130505-A1 | COMPOSITIONS AND METHODS FOR INHIBITING G PROTEIN SIGNALING | UNIVERSITY OF ROCHESTER (US) | 2010-05-27 | — | — | US | claimed |
| EP-2147310-A2 | COMPOSITIONS AND METHODS FOR INHIBITING G PROTEIN SIGNALING | University of Rochester (US) | 2010-01-27 | — | — | EP | claimed |
| WO-2009020677-A9 | COMPOSITIONS AND METHODS FOR INHIBITING G PROTEIN SIGNALING | UNIV ROCHESTER (US) | 2009-04-16 | — | — | WO | claimed |
| WO-2009020677-A2 | COMPOSITIONS AND METHODS FOR INHIBITING G PROTEIN SIGNALING | UNIVERSITY OF ROCHESTER (US) | 2009-02-12 | — | — | WO | claimed |
| US-8975259-B2 | Compositions and methods for inhibiting G protein signaling | UNIVERSITY OF ROCHESTER (US) | 2015-03-10 | — | — | US | disclosed |
| US-20120184693-A1 | ETHYLENE POLYMER PREPARATION METHOD | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-07-19 | — | — | US | disclosed |
| US-20100130505-A1 | COMPOSITIONS AND METHODS FOR INHIBITING G PROTEIN SIGNALING | UNIVERSITY OF ROCHESTER (US) | 2010-05-27 | — | — | US | disclosed |
| EP-2147310-A2 | COMPOSITIONS AND METHODS FOR INHIBITING G PROTEIN SIGNALING | University of Rochester (US) | 2010-01-27 | — | — | EP | disclosed |
| WO-2009020677-A9 | COMPOSITIONS AND METHODS FOR INHIBITING G PROTEIN SIGNALING | UNIV ROCHESTER (US) | 2009-04-16 | — | — | WO | disclosed |
| WO-2009020677-A2 | COMPOSITIONS AND METHODS FOR INHIBITING G PROTEIN SIGNALING | UNIVERSITY OF ROCHESTER (US) | 2009-02-12 | — | — | WO | disclosed |
| EP-1417202-A2 | AMINOPIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2004-05-12 | — | — | EP | disclosed |
| US-20030069276-A1 | Amino piperidine derivatives | F.HOFFMANN-LA ROCHE AG (CH) | 2003-04-10 | — | — | US | disclosed |
| WO-2002079186-A2 | AMINOPIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2002-10-10 | — | — | WO | disclosed |
| EP-0941084-A1 | RAF KINASE INHIBITORS | ZENECA LIMITED (GB) | 1999-09-15 | — | — | EP | disclosed |
| WO-1998022103-A1 | RAF KINASE INHIBITORS | ZENECA LIMITED (GB) | 1998-05-28 | — | — | WO | disclosed |
| EP-0035228-B1 | TETRAZOLE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF, AND ANTI-ULCER COMPOSITION CONTAINING THE SAME | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1985-01-02 | — | — | EP | disclosed |
| US-4372953-A | Tetrazole derivatives, and anti-ulcer composition containing the same | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1983-02-08 | — | — | US | disclosed |
| EP-0035228-A1 | Tetrazole derivatives, process for the preparation thereof, and anti-ulcer composition containing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1981-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069276-A1 | Amino piperidine derivatives | CCR5, CCR2, CXCR4 | KDM4E 784/4885GAA 4371/4885MAPT 4405/4885 |
| US-20100130505-A1 | COMPOSITIONS AND METHODS FOR INHIBITING G PROTEIN SIGNALING | GNAI1, GNAI3, GNAI2 | KDM4E 4575/4885GAA 1115/4885MAPT 3637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.